Concomitant intraperitoneal and systemic chemotherapy in patients with extensive peritoneal carcinomatosis of colorectal origi
Recruiting
- Conditions
- Peritoneal carcinomatosis Colorectal cancerIntraperitoneal chemotherapy
- Registration Number
- NL-OMON23907
- Lead Sponsor
- Erasmus Medical Center Rotterdam
- Brief Summary
de Boer NL, Brandt-Kerkhof ARM, de High IHJT, Mathijssen AHJ, van Meerten E, Creemers GJ, Verhoef C, Burger JWA. Gelijktijdige intraperitoneale en systemische chemotherapie voor patiënten met uitgebreide peritonitis carcinomatosa van colorectale origine: de INTERACT-trial. Nederlands Tijdschrift voor Oncologie, november 2019.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 33
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
•Patients with a histologically confirmed diagnosis of colorectal cancer
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This project will establish the maximum tolerable dose and recommended phase II dose of intraperitoneal irinotecan added to systemic FOLFOX + bevacizumab.
- Secondary Outcome Measures
Name Time Method Secondary endpoints are to explore the safety and feasibility of this treatment and to establish the pharmacokinetic profile of intraperitoneal administered irinotecan. During this study we will also collect and store ascites for (future) translational research purposes.